Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Sabe, Michel
Kirschner, Matthias
and
Kaiser, Stefan
2019.
Prodopaminergic Drugs for Treating the Negative Symptoms of Schizophrenia.
Journal of Clinical Psychopharmacology,
Vol. 39,
Issue. 6,
p.
658.
Young, Jared W.
Roberts, Benjamin Z.
Breier, Michelle
and
Swerdlow, Neal R.
2020.
Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment.
Psychopharmacology,
Vol. 237,
Issue. 7,
p.
1959.
Kapur, Ajay
2020.
Is Methylphenidate Beneficial and Safe in Pharmacological Cognitive Enhancement?.
CNS Drugs,
Vol. 34,
Issue. 10,
p.
1045.
Müller-Sedgwick, Ulrich
and
Sedgwick-Müller, Jane A.
2020.
Seminars in Clinical Psychopharmacology.
p.
392.
Bez, Yasin
Kompella, Sindhura
Gallucci, Felicia
Awerbuch, Adam
and
Coffey, Barbara J.
2021.
Clinical Use of Clozapine Serum Level and Management of Adverse Effects in an Adolescent with Difficult to Treat Schizophrenia.
Journal of Child and Adolescent Psychopharmacology,
Vol. 31,
Issue. 10,
p.
699.
Novitsky, M. A.
De Sousa, A.
Asadullin, A. R.
Gavrilyuk, O. A.
Petrov, A. V.
and
Nasyrova, R. F.
2021.
Possibilities and limitations of antidepressant use to correct depressive and negative symptoms in schizophrenia.
Personalized Psychiatry and Neurology,
Vol. 1,
Issue. 2,
p.
21.
Mistarz, Nicolaj
Andersen, Kjeld
Nielsen, Anette Søgaard
Goudriaan, Anneke E.
Michel, Tanja Maria
Skøt, Lotte
Nielsen, Dorthe Grüner
and
Mellentin, Angelina Isabella
2021.
Pharmacological enhancing agents targeting cognition in patients with alcohol-induced neurocognitive disorders: A systematic review.
Neuroscience & Biobehavioral Reviews,
Vol. 125,
Issue. ,
p.
608.
Gering, A.
Fourneret, P.
Poulet, E.
Geoffray, M.-M.
and
Jurek, L.
2021.
TDAH dans l’enfance et trouble psychotique à l’âge adulte : quel lien ?.
L'Encéphale,
Vol. 47,
Issue. 5,
p.
484.
Corbeil, Olivier
Bérubé, Félix-Antoine
Artaud, Laurence
and
Roy, Marc-André
2021.
Détecter et traiter les troubles comorbides aux premiers épisodes psychotiques : un levier pour le rétablissement.
Santé mentale au Québec,
Vol. 46,
Issue. 2,
p.
307.
Shen, Jie
Shan, J.
Liang, B.
Zhang, D.
Tang, H.
Zhong, L.
and
Li, M.
2022.
Effects of Atomoxetine Hydrochloride on Regulation of Lifespan in Drosophila Model.
The Journal of nutrition, health and aging,
Vol. 26,
Issue. 2,
p.
203.
Rubio, Jose M.
and
Kane, John M.
2022.
The pharmacological treatment of schizophrenia: How far have we come?.
Psychiatry and Clinical Neurosciences Reports,
Vol. 1,
Issue. 2,
Osugo, Martin
Whitehurst, Thomas
Shatalina, Ekaterina
Townsend, Leigh
O’Brien, Oisin
Mak, Tsz Lun Allenis
McCutcheon, Robert
and
Howes, Oliver
2022.
Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials.
Neuroscience & Biobehavioral Reviews,
Vol. 135,
Issue. ,
p.
104568.
Gémes, Katalin
Taipale, Heidi
Björkenstam, Emma
Rahman, Syed
Gustafsson, Klas
Tanskanen, Antti
Ekselius, Lisa
Mittendorfer-Rutz, Ellenor
and
Helgesson, Magnus
2023.
The role of sociodemographic and clinical factors in the initiation and discontinuation of attention deficit hyperactivity disorder medication among young adults in Sweden.
Frontiers in Psychiatry,
Vol. 14,
Issue. ,
Corbeil, Olivier
Brodeur, Sébastien
Courteau, Josiane
Béchard, Laurent
Huot-Lavoie, Maxime
Angelopoulos, Elaine
Di Stefano, Samanta
Marrone, Erica
Vanasse, Alain
Fleury, Marie-Josée
Stip, Emmanuel
Lesage, Alain
Joober, Ridha
Demers, Marie-France
and
Roy, Marc-André
2024.
Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting.
The British Journal of Psychiatry,
Vol. 224,
Issue. 3,
p.
98.
Mäkipelto, Ville
Tuulio-Henriksson, Annamari
Hakulinen, Christian
Niemelä, Solja
Lähteenvuo, Markku
Wegelius, Asko
Kieseppä, Tuula
Isometsä, Erkki
Tiihonen, Jari
Kampman, Olli
Lahdensuo, Kaisla
Mazumder, Atiqul
Suvisaari, Jaana
and
Holm, Minna
2024.
Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
Schizophrenia Research,
Vol. 266,
Issue. ,
p.
118.
Arsenault‐Mehta, Kyle
Hochman‐Bérard, Mario
Johnson, Alexander
Semenova, Dar'ya
Nguyen, Bea
Willis, Jessie
Mouravska, Natalia
Joober, Ridha
and
Zhand, Naista
2024.
Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review.
Neuropsychopharmacology Reports,
Vol. 44,
Issue. 1,
p.
2.
Ramasubbu, Cynthia
Poonia, Sukhpreet
Brady-Randle, Erin
Schutz, Christian G.
and
Rafizadeh, Reza
2025.
Psychostimulant Substitution Therapy for the Treatment of Stimulant Use Disorders in Patients with Schizophrenia or Schizoaffective Disorder: A Systematic Review.
Journal of Dual Diagnosis,
Vol. 21,
Issue. 2,
p.
167.
Luykx, Jurjen J.
Corbeil, Olivier
Kärkkäinen, Olli
Tanskanen, Antti
Mittendorfer-Rutz, Ellenor
Tiihonen, Jari
and
Taipale, Heidi
2025.
Long term safety of ADHD medication in patients with schizophrenia spectrum disorders.
Molecular Psychiatry,